Powder: -20°C for 3 years | In solvent: -80°C for 1 year
PE859 是 tau 和 Aβ 聚集的有效抑制剂,IC50值分别为 0.66 和 1.2 μM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 978 | 现货 | ||
2 mg | ¥ 1,460 | 现货 | ||
5 mg | ¥ 2,490 | 现货 | ||
10 mg | ¥ 3,810 | 现货 | ||
25 mg | ¥ 6,130 | 现货 | ||
50 mg | ¥ 8,450 | 现货 | ||
100 mg | ¥ 11,300 | 现货 | ||
500 mg | ¥ 22,800 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 2,590 | 现货 |
产品描述 | PE859 is a potent inhibitor of both tau and Aβ aggregation. |
靶点活性 | β-Amyloid:1.2 μM, Tau:0.66 μM |
体外活性 | In an Alzheimer's patient's brain, senile plaques and neurofibrillary tangles, the abnormal aggregates of amyloid β (Aβ) peptide and Tau Protein, are observed as the two major hallmarks of this disease. PE859 inhibits the heparin-induced aggregation of both 3RMBD and full length tau in a concentration-dependent manner. In each assay, the IC50 values calculated at the last measurement periods are 0.81 μM, and 2.23 μM, respectively. PE859 inhibits tau aggregation through the formation of a beta-sheet structure[2]. |
体内活性 | PE859 is able to cross the blood-brain barrier and thus PE859 could be distributed into the tissues of the central nervous system. The maximum concentration of PE859 is 2.005 μg/mL in the blood at 3 h and 1.428 μg/g in the brain at 6 h. PE859 delays onset and progression of the motor dysfunction in JNPL3 mice. PE859 delays progression of the motor dysfunction through the inhibition of accumulation of sarkosyl-insoluble tau. [2] |
激酶实验 | PEL cells are incubated in triplicate in a 96-well microculture plate in the presence of different concentrations of methyl-β-cyclodextrin (0-10 mM) in a final volume of 0.1 mL for 24 h at 37°C. Subsequently, MTT (0.5 mg/mL final concentration) is added to each well. After 3 h of additional incubation, 100 μL of a 0.04 N HCl is added to dissolve the crystals. Absorption values at 570 nm are determined. |
分子量 | 448.52 |
分子式 | C28H24N4O2 |
CAS No. | 1402727-29-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 30 mg/mL
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
PE859 1402727-29-0 Cytoskeletal Signaling Neuroscience Proteases/Proteasome Stem Cells Beta Amyloid Gamma-secretase Microtubule Associated PE 859 Inhibitor PE-859 inhibit Microtubule/Tubulin inhibitor